Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

İÇLİ, FİKRİ; Altundag, Kadri; AKBULUT, HAKAN; PAYDAŞ, SEMRA; BAŞARAN, Gül; Saip, Pinar; GÖKÖZ DOĞU, Gamze; Erlap, Yesim; Uslu, Ruchan; Sevinc, Alper; Onur, Handan; Mandel, Nil; Sezgin, Canfeza; Altinbas, Mustafa; Guler, Nilufer; Isikdogan, Abdurrahman; GÖKMEN, ERHAN; UYGUN, KAZIM; Ustuner, Zeki; YAREN, ARZU; Demirkan, HATİCE; Coskun, Ugur; Ata, Alper; ÖZKAN, METİN; Arican, Ali

doi:10.1007/s12282-013-0506-y

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Atıf İçin Kopyala

İÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., Saip P., ...Daha Fazla

BREAST CANCER, cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 5
Basım Tarihi: 2015
Doi Numarası: 10.1007/s12282-013-0506-y
Dergi Adı: BREAST CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.480-485
Anahtar Kelimeler: Adjuvant treatment, Nine weeks trastuzumab, Cardiotoxicity, Early breast cancer, CHEMOTHERAPY, XENOGRAFTS, ANTIBODY, RECEPTOR, THERAPY
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.